[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hanlim Pharm. Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635415","phase-3-clinical-trial-to-evaluate-the-efficacy-and-safety-of-monotherapy-group-of-hl1113r1-or-hl1113r2-versus-hl1113-fixed-dose-combination-in-patients-with-essential-hypertension-and-type-ii-diabetes-mellitus-100635415",false,"NCT07552389","Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus","A Randomized, Active Controlled, Double Blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus","Inclusion Criteria:\n\n* Adult male or female subjects aged ≥19 years at the time of written informed consent.\n* Subjects diagnosed with essential hypertension accompanied by type 2 diabetes mellitus.\n* etc.\n\nExclusion Criteria:\n\n* Subjects whose blood pressure measured in the selected arm at both screening and randomization meets the following criterion: MSDBP ≥ 110 mmHg\n* Subjects whose blood pressure measured three consecutive times in each arm at intervals of at least 2 minutes at screening shows a difference of ≥20 mmHg in SBP and ≥10 mmHg in DBP.\n* etc.","ALL","19 Years",{"count":19,"type":20},228,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus",[26,27],"Hypertension","Diabete Type 2","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-27","ACTUAL",{"date":34,"type":32},"2025-12-18",{"date":36,"type":20},"2028-12",{"name":38,"class":39},"Hanlim Pharm. Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100530550","the-prescription-patterns-and-clinical-efficacy-of-tenero-tabtenero-m-sr-tab-100530550","NCT06188234","The Prescription Patterns and Clinical Efficacy of Tenero Tab\u002FTenero M SR Tab","Observational Study on the Prescription Patterns and Clinical Efficacy of Tenero Tab\u002FTenero M SR Tab in Korean Type 2 Diabetes Mellitus Patients","Inclusion Criteria:\n\n1. Adults over 19 years of age\n2. Individuals diagnosed with type 2 diabetes.\n3. Individuals who, at the clinical discretion, are prescribed Tenero Tab or Tenero M SR Tab for the purpose of diabetes treatment for the first time.\n4. Individuals who have voluntarily provided written consent to participate in this study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Individuals who are contraindicated according to the approved indications of Tenero Tab\u002FTenero M SR Tab.\n3. Other cases where the principal investigator and study personnel deem individuals ineligible for participation in this clinical trial.",{"count":49,"type":20},3000,"OBSERVATIONAL","This study is to observe the prescription patterns and clinical efficacy of patients prescribed with Tenero Tab\u002FTenero M SR Tab for diabetes treatment in routine clinical practice.",[53],"Diabetes Mellitus, Type 2",[55,56],"Metformin HCI","Teneligliptin hydrochloride","2024-02-13",{"date":59,"type":32},"2024-02-15",{"date":61,"type":32},"2022-12-27",{"date":63,"type":20},"2026-06",{"name":38,"class":39},""]